NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/02/2026
Voltar para busca
Dado oficial do USPTO
TOPO THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
TOPO THERAPEUTICS
ST13
US500000098977477Classe
42
Pedido
98977477
Registro
8139101
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
44
Atualização mais recente
11/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
15/07/2024
Data de registro
10/02/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/02/2026
Última transação
11/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
17/09/2024
Primeiro uso no comércio
17/09/2024
Código do desenho
4
Tipo de titular
03
Localização do titular
Watertown, MA
Examinador
HARMON, RAYMOND E
Unidade examinadora
L30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Topo Therapeutics, Inc.
Topo Therapeutics, Inc.
Representantes
Susan Weller Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research for the purpose of treating pain disorders, folding disorders, and secretory diarrhea; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine
Publicações
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
10/02/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
22/01/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
22/01/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
22/01/2026
DPCC
DIVISIONAL PROCESSING COMPLETE
22/01/2026
IUAF
USE AMENDMENT FILED
21/01/2026
DRRR
DIVISIONAL REQUEST RECEIVED
21/01/2026
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
21/01/2026
EISU
TEAS STATEMENT OF USE RECEIVED
21/01/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/01/2026
EX1G
SOU EXTENSION 1 GRANTED
08/01/2026
EXT1
SOU EXTENSION 1 FILED
08/01/2026
EEXT
SOU TEAS EXTENSION RECEIVED
08/01/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/11/2025
CORV
REVIEW OF CORRESPONDENCE COMPLETE
19/11/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
19/11/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/09/2025
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
18/09/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/08/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/08/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/08/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/08/2025
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
06/07/2025
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
26/03/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/02/2025
PUBO
PUBLISHED FOR OPPOSITION
25/02/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/02/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/01/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
30/01/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
30/01/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
30/01/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
30/01/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
29/01/2025
GNRT
NON-FINAL ACTION E-MAILED
29/01/2025
CNRT
NON-FINAL ACTION WRITTEN
29/01/2025
DOCK
ASSIGNED TO EXAMINER
28/01/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/01/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/11/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/11/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/11/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/11/2024
NWAP
NEW APPLICATION ENTERED
15/07/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TOPO THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.